Sjögren's disease: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• CD19 13
• JAK 0
• BCMA 5
• IL-17 0
• mTOR 0
• STAT3 0
• AQP4 0
• CD40 1
• CTLA-4 1
• NRF2 0
• PD-1 1
• STING 0
• TIGIT 0
• IL-6 0
• PI3K 0
• AKT 0
• BCL-2 0
• CD20 1
• CD22 0
• CD38 0
• ERK 0
• FGFR 0
• G6PD 0
• GPX4 0
• IL-4 0
• JNK 0
• KEAP1 0
• MAPK 0
• MYC 0
• NLRP3 0
• NMDA 0
• PD-L1 1
• PPAR 0
• SIRT1 0
• TNF 0
• TP53 0

24 of 331 institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

No running funded project names this disease yet.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  Sjogren's Lung Study

  NCT04843345· Stanford University· Updated 9 Nov 2026

  “Change in research staffing”Registry text, quoted unchanged. Source

• Withdrawn

  Autologous CD19/BCMA Dual-Target CAR-T for Relapsed/Refractory Autoimmune Diseases

  NCT07361094· Beijing Boren Hospital· Updated 15 Oct 2026

  “No participants.”Registry text, quoted unchanged. Source

• Terminated

  A Study to Evaluate the Effects of ASP5502 in Healthy Adults and Adults With Primary Sjögren's Syndrome

  NCT06544642· Astellas Pharma Global Development, Inc.· Updated 14 Sept 2026

  “Company's strategic decision”Registry text, quoted unchanged. Source

• Suspended

  A Study of BEN301 Injection in theTreatment of Autoimmune Diseases

  NCT07527936· RenJi Hospital· Updated 4 Jun 2026

  “company's decision”Registry text, quoted unchanged. Source

• Withdrawn

  Pregnancy and Medically Assisted Conception in Rare Diseases

  NCT02450396· Assistance Publique - Hôpitaux de Paris· Updated 27 Mar 2026

  “Abandonment of the study project”Registry text, quoted unchanged. Source

• Suspended

  Clinical Study on Targeted CD19CAR-T Therapy for Autoimmune Diseases

  NCT06549296· Nanjing Bioheng Biotech Co., Ltd.· Updated 3 Feb 2026

  “R\&D strategy adjustment”Registry text, quoted unchanged. Source

• Terminated

  Study to Evaluate Corneal Neurosensory Abnormalities in Patients With Sjögren's Dry Eye

  NCT06411132· Dompé Farmaceutici S.p.A· Updated 20 Nov 2025

  “The analyses presented are based on a database lock date of 05 March 2025.The study was prematurely interrupted by Dompé following a review of the database, which determined that an acceptable no. of patients was reached to meet the trial objectives.”Registry text, quoted unchanged. Source

• Terminated

  RHPRG4 FOR THE TREATMENT OF SJÖGREN'S RELATED DRY EYE DISEASE

  NCT06520202· Lubris Bio Pty Ltd· Updated 29 Sept 2025

  “Efficacy signal substantial enough to move to a larger sturdy”Registry text, quoted unchanged. Source

• Terminated

  Differences in Corneal Structure and Function in Patients With Sjogrens vs. Non-Sjogrens Dry Eye

  NCT06364657· Johns Hopkins University· Updated 15 Jan 2025

  “The study was prematurely closed to enrollment due to the principal investigator's departure from the institution (Johns Hopkins University).”Registry text, quoted unchanged. Source

• Withdrawn

  Anti-BTLA Agonist Therapy in Subjects With Primary Sjogren's Syndrome

  NCT05781451· Stanford University· Updated 17 Apr 2024

  “Drug unavailable”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

  NCT03816345· National Cancer Institute (NCI)· Source

• Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren's Syndrome

  NCT04496960· National Institute of Dental and Craniofacial Research (NIDCR)· Source

• The Myelin Disorders Biorepository Project

  NCT03047369· Children's Hospital of Philadelphia· Source

• Nipocalimab in Moderate to Severe Sjogren's Disease

  NCT06741969· Janssen Research & Development, LLC· Source

• A Phase 2a/b Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Sjögren's Disease

  NCT07737743· Novartis Pharmaceuticals· Source

• Two Arm, Double-blind, Phase III Study Assessing Efficacy and Safety of Ianalumab Versus Placebo, in Participants With Sjögren's Disease With High Symptom Burden

  NCT07621809· Novartis Pharmaceuticals· Source

• A Trial in Healthy Adult Participants and Adults With Autoimmune Diseases to Test How HBM7020 is Tolerated and How it Behaves in the Body

  NCT07649265· Otsuka Pharmaceutical Development & Commercialization, Inc.· Source

• A Study of Nipocalimab in Adults With Primary Sjogren's Syndrome (pSS)

  NCT04968912· Janssen Research & Development, LLC· Source

• Umbilical Cord Mesenchymal Stem Cell Secretome in Patients With Sjogren's Syndrome

  NCT07910526· Universitas Sebelas Maret Hospital· Source

• Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren Disease

  NCT07281456· National Institute of Dental and Craniofacial Research (NIDCR)· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 15
• Organoids 3
• Mendelian Randomization Analysis 20
• Gene Expression Profiling 31
• Sequence Analysis, RNA 6
• Exome Sequencing 2
• Proteomics 7
• Metabolomics 9
• Mass Spectrometry 1
• Flow Cytometry 11
• Immunohistochemistry 5
• Positron-Emission Tomography 1
• Magnetic Resonance Imaging 17
• Machine Learning 17
• Deep Learning 4
• Cohort Studies 35
• Genome-Wide Association Study 24

• Novel clinical phenotype-based stratification identifies distinct immunopathological and ultrasonographic signatures in Sjögren's disease.

  Rheumatology (Oxford), Sept 2026

• Sjögren's disease patients with no hyposalivation and with short oral dryness complaints contain more T cells in salivary gland parenchyma.

  Rheumatology (Oxford), Sept 2026

• Minor salivary gland biopsies in childhood-onset Sjögren's disease show greater inflammation and more frequent fibrotic changes than in adult-onset Sjögren's disease.

  Arthritis Res Ther, Jul 2026

• Metformin improves salivary gland inflammation and hypofunction in murine Sjögren's syndrome.

  Arthritis Res Ther, Jun 2019

• Epigallocatechin gallate stimulates the neuroreactive salivary secretomotor system in autoimmune sialadenitis of MRL-Fas(lpr) mice via activation of cAMP-dependent protein kinase A and inactivation of nuclear factor κB.

  Autoimmunity, Jan 2015

See which targets of this disease your abstract mentions, and go to the people working on them.